Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial.

Trial Profile

Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Levofloxacin (Primary) ; Amoxicillin; Lansoprazole; Metronidazole
  • Indications Helicobacter pylori infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Feb 2016 Status changed from active, no longer recruiting to completed, according to results published in the American Journal of Gastroenterology.
    • 02 Feb 2016 Primary endpoint of eradication rate in the second line therapy has been met, according to results published in the American Journal of Gastroenterology.
    • 02 Feb 2016 Results published in the American Journal of Gastroenterology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top